Wegovy maker Novo's profit warning wipes out $70B in market value after shares plunge 30%

Novo Nordisk's market value plunged by $70 billion, with shares dropping nearly 30%, after the company issued a significant profit warning and appointed Maziar Mike Doustdar as its new CEO. The drugmaker slashed its 2025 sales growth outlook to 8-14% from 13-21%, citing lower second-half growth expectations for Wegovy and Ozempic in the crucial U.S. market. This downgrade is primarily attributed to intensifying competition, notably from Eli Lilly's Zepbound surpassing Wegovy prescriptions, and the unexpected persistence of market share loss to compounded GLP-1 drugs despite recent FDA actions. The new CEO, an insider, faces the urgent task of reviving the company's performance in the U.S. amidst these competitive and regulatory challenges.

Analysis

Novo Nordisk experienced a catastrophic loss of $70 billion in market value after its shares plunged nearly 30% in response to a severe profit warning and a change in leadership. The company drastically cut its 2025 sales growth forecast from a range of 13-21% down to 8-14%, a move a major shareholder described as a "shocker." This revision is attributed to two critical challenges in the U.S. market: unexpectedly persistent competition from compounded GLP-1 drugs and the loss of market leadership to a branded rival. Despite an FDA ban intended to curb compounded versions of Wegovy, Novo's CFO confirmed that approximately one million U.S. patients continue to use these alternatives, a market reality the company previously underestimated. Compounding this issue, rival Eli Lilly's Zepbound has now surpassed Wegovy in weekly prescriptions, eroding Novo's first-mover advantage. The appointment of insider Maziar Mike Doustdar as the new CEO is a direct response to this crisis, with an explicit mandate to restore performance, particularly in the United States, as the stock languishes down 44% for the year.

Key Decisions for Investors

• Investors should reassess their position in Novo Nordisk given the magnitude of the guidance cut, which signals that headwinds from both compounded drugs and branded competition are more severe and persistent than previously communicated.
• Monitor prescription data for Wegovy versus Eli Lilly's Zepbound closely, as a continued or accelerating loss of market share would validate the negative outlook and indicate further downside risk.
• Watch for any tangible evidence or new strategies from the incoming CEO and management team on effectively combating the market share erosion from compounded GLP-1 drugs, as progress on this front is critical to rebuilding investor confidence and stabilizing sales forecasts.